PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35480532-0	2022	Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses.	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	31-37	
26951202-1	2016	BACKGROUND AND OBJECTIVE: Although there is evidence indicating cytochome P450 (CYP) 1A2 is responsible for the metabolism of rasagiline, the role of other CYP isoforms is unclear.	rasagiline	126-136	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	74-88	
18488080-6	2007	Rasagiline undergoes extensive hepatic metabolism primarily by cytochrome P450 type 1A2 (CYP1A2).	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	63-87	
18488080-6	2007	Rasagiline undergoes extensive hepatic metabolism primarily by cytochrome P450 type 1A2 (CYP1A2).	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95	
17296539-12	2006	CYP1A2 inhibitors slow the elimination of rasagiline and mandate dosage reduction.	rasagiline	42-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6	
35480532-1	2022	Objectives: Rasagiline, a drug for Parkinson"s disease is metabolized by CYP1A2 enzyme.	rasagiline	12-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	73-79	
35480532-2	2022	The objective of the study was to investigate the influence of cytochrome P450 1A2 variants and smoking status of healthy individuals on the pharmacokinetics of rasagiline.	rasagiline	161-171	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	63-82	
35480532-13	2022	Conclusion: The study concludes that the systemic metabolism of rasagiline is significantly increased in CYP1A2*AA variants while smoking status did not show consistent difference in PK parameters.	rasagiline	64-74	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	105-111